Monoamine oxidase inhibitors (MAOI) may possibly inhibit barbiturate metabolism and extend barbiturate outcomes; watch closely
pentobarbital will lower the extent or outcome of nicardipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will reduce the level or effect of tamoxifen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lessen the extent or outcome of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.
benzhydrocodone/acetaminophen and pentobarbital both of those increase sedation. Stay clear of or Use Alternate Drug. Restrict use to sufferers for whom alternative cure options are insufficient
pentobarbital will minimize the extent or impact of vinorelbine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
Either boosts toxicity of the opposite by pharmacodynamic synergism. Stay away from or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may perhaps final result if coadministered. Reserve concomitant prescribing of these medication in patients for whom other remedy choices are insufficient. Restrict dosages and durations for the minimum essential. Monitor closely for signs of respiratory despair and sedation.
Check Carefully (3)pentobarbital will lower the level or impact of diazepam intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. Powerful or moderate CYP3A4 inducers may perhaps increase amount of diazepam elimination; consequently, efficacy of diazepam might be decreased.
With therapeutic doses of TCAs, barbiturates boost metabolism and reduce blood concentrations of TCAs.
pentobarbital will decrease the level or impact of vincristine liposomal by influencing hepatic/intestinal enzyme 戊巴比妥鈉製作 CYP3A4 metabolism. Minimal/Significance Mysterious.
pentobarbital will lower the level or impact of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
Keep track of Intently (1)pentobarbital will minimize the extent or outcome of exemestane by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. For people receiving exemestane with a powerful CYP3A4 inducer the recommended dose of exemestane is fifty mg daily following a food.
pentobarbital will lessen the extent or result of bedaquiline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Avoid coadministration of bedaquiline with potent CYP3A4 inducers resulting from possible for decreased therapeutic influence
pentobarbital improves toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. CYP3A4 inducers could raise the metabolism of ifosfamide to its Energetic alkylating metabolites.